Leakproof Connection Integrity Test For Devices Intended for Handling Hazardous Drugs devteam on May 6, 2022 Post navigation Previous: Previous post: Treatment time, ease of use and cost associated with use of Equashield™, PhaSeal®, or no closed system transfer device for administration of cancer chemotherapy to a dog modeNext: Next post: Fluorescent Evaluation of Dry Connections in the EQUASHIELD™ , Phaseal® and Tevadaptor®/Onguard™ Closed System Drug Transfer Devices